Posted on 04/30/2025 2:50:29 PM PDT by Morgana
A major study just revealed that the abortion drug mifepristone is far more dangerous than U.S. health agencies have admitted, prompting calls for President Donald Trump’s Food and Drug Administration (FDA) to reinstate more stringent safeguards surrounding the drug’s prescription and use, reinvestigate the health risks, and if warranted, reconsider its approval altogether.
The Ethics and Public Policy Center (EPPC) released its report Monday, revealing that the rate of serious adverse complications associated with mifepristone is at least 22 times higher than the 0.5% touted by the FDA.
In a letter to FDA Commissioner Marty Makary, Senator Josh Hawley (R-Mo.) joined the EPPC in demanding that the guidelines for administering mifepristone originally in place when the FDA approved the drug in 2000 be reinstated.
“An alarming new study has revealed that the safety risk of the chemical abortion drug, mifepristone, are far greater than the FDA currently acknowledges,” Hawley wrote. He continued, “I urge you to follow this new data and take all appropriate action to restore critical safeguards on the use of mifepristone. The health and safety of American women depend on it.” The senator concluded, “The time to act is now. It is time to revisit and restore the FDA’s longstanding safety measures governing mifepristone.”
Makary pledged last week to review new data regarding the safety of mifepristone, although he had not made a similar pledge when pressed by Hawley on the issue during his confirmation hearing before the Senate. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. had previously told Republican senators that he plans to “study the safety of mifepristone” and implement policies consistent with the president’s position on the abortion drug. Kennedy said that the president “has not yet taken a stand on how to regulate it. Whatever he does, I will implement those policies.”
In comments to The Washington Stand, Mary Szoch, director of the Center for Human Dignity at Family Research Council, said, “I am encouraged to know that FDA Commissioner Makary will remain true to his roots as a scientist and examine all of the data on mifepristone. The newest data shows one in 10 women has a serious adverse event following the use of mifepristone.” She added, “I look forward to seeing the steps Director Makary will take in light of how dangerous this drug is for women.”
Regarding the results of the EPPC study, Szoch stated, “The FDA has never thoroughly investigated the impact of mifepristone on all women.” Noting the high rate of serious complications associated with mifepristone — more than one in nine women — she continued, “That number doesn’t even begin to touch the number of women who have serious psychological issues after seeing their clearly recognizable unborn baby dead in the toilet as the result of a mifepristone abortion. The FDA must re-examine mifepristone and revoke its approval.”
EPPC President Ryan Anderson, who co-authored the study, appeared on Monday night’s “Washington Watch” to discuss his findings. He clarified, “The major takeaway here is that it’s a 22-times-higher rate of serious adverse events for women who take the chemical abortion drug than what the FDA claims on the label.” He continued, “Why do we see such poor outcomes? Both the Obama and the Biden administrations got rid of almost all of the major safety protections that the FDA originally required when they approved of the pill. So what we’re calling on the Trump FDA to do is … reinstate those original safety provisions.”
Anderson also noted that, since the FDA has removed the requirement that mifepristone must be prescribed by a physician and dispensed and consumed in the physician’s office, the abortion drug has been increasingly ordered online or via “telehealth mail order” and has even been shipped across state lines, including into states with strong pro-life laws in place. He explained that “many blue states” are “mailing the abortion pill across state lines.”
Noting that the president has previously averred that the issue of abortion ought to be left to the states, Anderson continued, “Well, you can’t leave it to the states if California is mailing abortion pills to the other 49 states. You can’t make America healthy again if you have a 10.9% rate of serious adverse events. And you can’t undo all the stupid things Biden and Obama did unless you also undo what they did to the abortion pill. So that’s what we’re calling on the Trump FDA to do here.”
Also on Monday night’s episode of “Washington Watch,” Dr. Donna Harrison, director of research for the American Association of Pro-Life Obstetricians and Gynecologists, said that her experience as an obstetrician/gynecologist confirms the EPPC study’s findings. She explained that doctors “across the country are seeing similar kinds of things in the [emergency room], seeing women with hemorrhages, women with tissue left inside, women who have ectopic pregnancies that never should have gotten the abortion pill at all. And they got it because they never had an in-patient visit, they never had an ultrasound,” because the FDA does not require it.
Harrison also explained that the FDA based its guidelines on clinical studies, which do not provide accurate data that corresponds to how the abortion drug is administered and used in the real world, especially without stringent safeguards in place. “Clinical trials are done under very controlled circumstances,” Harrison said. She noted that women who participated in these clinical trials had ultrasound results, were tested for ectopic pregnancies, were within a certain gestational timeframe, and were excluded from the trial if they did not meet specific criteria. She said, “So these trials sought out healthy women where their gestational age, the dating of the pregnancy, is perfectly known. And then they’re followed very, very, very carefully. That’s not what happens in the real world.”
Harrison detailed, “In the real world, Sally Smith, who may be 14, gets online, gives her gift credit card, and gets mailed mifeprex [the brand name for mifepristone]. She has no idea how far along she is. She may think that she’s eight weeks. And I’ve seen cases where women were told, ‘Oh, you’re eight weeks along,’ and they take the mifeprex and they deliver a 22-week baby who could have survived if that baby had been delivered under the right circumstances. It’s this kind of horrendous care…”
Anderson also criticized the FDA’s handling of the dangers of mifepristone. “[W]hat we saw in the Obama years and now, most recently, from the Biden administration, it was clearly politicized medicine to get rid of these original safety provisions,” Anderson continued. He noted that regulations such as requiring multiple in-person physician visits, requiring a physician to prescribe mifepristone, requiring that the abortion drug be dispensed and consumed in the physician’s office, requiring a follow-up appointment, and requiring adverse complications be reported were eliminated by the Obama and Biden administrations. Anderson stated, “This isn’t looking out for the best interest of women. Certainly not looking out for the best interest of their unborn children.”
I’d give them a warning beforehand. Some things need to sink in before the majority can go along.
PP has told them for decades that it is safe. Just like the drugs they pump into kids to make them transgender.
Drugs have almost became religions.
Covid vaccine.
Abortion pill.
Ozempic.
These pills are almost 100% fatal.
Karma ...take the pill to kill your baby and the dead baby kills you with sepsis.
I’m jaded and and angry.
Let them know of the risk, then let them suffer the consequences of killing their baby.
RU486 is nasty business.
I agree. Put on a warning label.
most women aren’t ready to see their dead fetus on the bathroom floor - it’s not just the physical pain
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.